Oral and systemic treatments for psoriasis, compared

Five pill-form, non-biologic options exist for psoriasis: methotrexate, cyclosporine, acitretin, apremilast, and deucravacitinib. All five work throughout the body rather than on the skin alone, which is what separates them from a topical cream or phototherapy. They do not all work the same way. Methotrexate and cyclosporine are older immune-suppressing medicines - methotrexate slows skin-cell growth and calms immune overactivity, cyclosporine slows the growth of specific overactive immune cells. Acitretin is a retinoid, related to vitamin A. Unlike the other two, it does not suppress the immune system at all. That is why it is sometimes chosen for someone who cannot take an immune-suppressing drug. Apremilast and deucravacitinib are newer, more targeted oral drugs. Apremilast raises a molecule called cAMP inside immune cells to dial down several inflammatory signals. Deucravacitinib blocks a specific enzyme (TYK2) using a mechanism the label calls allosteric inhibition. Each one has its own full page with complete label detail.⌁ Evidence⌁ Evidence⌁ Evidence

All five are generally used for moderate-to-severe psoriasis. Methotrexate can also treat psoriatic arthritis and nail psoriasis. Deucravacitinib is separately approved for active psoriatic arthritis. Apremilast is also approved for psoriatic arthritis and for the mouth ulcers of Behçet’s disease. Combination rules differ sharply between them. Cyclosporine’s label states it should not be given together with phototherapy, methotrexate, other immune-suppressing medicines, coal tar, or radiation therapy. Acitretin’s label rules out combining with methotrexate (raised liver-inflammation risk) and tetracycline antibiotics, and states that phototherapy doses need to be lowered if combined with it. Apremilast, by contrast, has been shown safe and effective combined with methotrexate, phototherapy, or topical treatments. Deucravacitinib’s label does not name phototherapy or topicals as a documented combination partner. It lists phototherapy as an alternative for the same eligible patients, not a partner drug.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

Dosing frequency varies more across this group than the name "oral" suggests. Methotrexate is taken once a week, never daily - the label warns that a mistaken daily dose has caused deaths. Cyclosporine is taken twice a day. Acitretin is taken once a day with food. Apremilast starts with a five-day dose increase before settling at twice a day (or once a day for the extended-release version). Deucravacitinib is a fixed once-a-day dose from day one, with no titration step. Response timelines also differ. Patient-education sources report visible improvement on cyclosporine as early as two weeks, while methotrexate and acitretin can take up to six months for full effect. Apremilast and deucravacitinib trial results are typically reported at week 16.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

Monitoring burden is one of the biggest practical differences between these five. Methotrexate and cyclosporine both require regular blood testing throughout treatment - cyclosporine’s label calls for blood-pressure and kidney-function checks every two weeks for the first three months. Acitretin requires liver-function and cholesterol testing, plus - for anyone who can become pregnant - pregnancy tests and strict contraception continuing three years after stopping. Apremilast needs no routine blood testing, but its label calls for weight and mood monitoring. Deucravacitinib checks liver enzymes only if you have known or suspected liver disease, a lighter routine-testing burden than methotrexate or cyclosporine. It still calls for a tuberculosis check before starting. Three of the five - methotrexate, cyclosporine, and acitretin - carry an FDA boxed warning, the agency’s strongest kind. Apremilast and deucravacitinib do not carry a boxed warning, though each has its own real warnings. Apremilast’s cover depression and weight loss; deucravacitinib’s cover infection, shingles, and a small reported lymphoma rate.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

Cost splits sharply along the same old-versus-new line as monitoring burden. Methotrexate, cyclosporine, and acitretin are older, generic medicines: live pharmacy-price snapshots showed coupon prices around $13 (methotrexate), $41 (cyclosporine), and $89 (acitretin) for a defined prescription. Apremilast and deucravacitinib have no generic version yet; snapshots showed retail cash prices in the thousands of dollars for a 30-day supply. Both manufacturers run a co-pay program that can bring the cost to as little as $0 a month for commercially insured patients. Both programs explicitly exclude anyone on Medicare, Medicaid, or another government-funded plan.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

SteadySkin does not yet have a documented community pattern comparing these five options against each other. No first-hand account from Ajith exists for any of them. Rather than guess, I say so honestly. Each drug’s own page says the same about that specific medicine.⌁ Evidence

Before starting, track which monitoring schedule applies to the option your dermatologist is suggesting. That ranges from none (apremilast, unless you have liver disease) to every two weeks (cyclosporine, for the first three months). If you start one, keep a dated dose log matching its schedule. That is weekly for methotrexate, twice daily for cyclosporine, once daily for acitretin or deucravacitinib, and through apremilast’s five-day titration. Add a same-conditions photo around that drug’s own response-timeline mark, so you and your dermatologist have something concrete to compare against your starting point.⌁ Evidence